Reboxetine treatment of depression in Parkinson's disease.

  • M. R. Lemke
  • Published 2000 in The Journal of clinical psychiatry


Sir: The efficacy and tolerability of reboxetine, a norepinephrine reuptake inhibitor, have been shown in patients with major depressive disorder or dysthymia. This novel antidepressant shows negligible effects on psychomotor and cognitive function and may be especially effective in improving negative self-perception and lack of motivation toward action… (More)

2 Figures and Tables